Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial

Autor: Kevin J. Anstrom, Imre Noth, Kevin R. Flaherty, Rex H. Edwards, Joan Albright, Amanda Baucom, Maria Brooks, Allan B. Clark, Emily S. Clausen, Michael T. Durheim, Dong-Yun Kim, Jerry Kirchner, Justin M. Oldham, Laurie D. Snyder, Andrew M. Wilson, Stephen R. Wisniewski, Eric Yow, Fernando J. Martinez, For the CleanUP-IPF Study Team
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Respiratory Research, Vol 21, Iss 1, Pp 1-13 (2020)
Druh dokumentu: article
ISSN: 1465-993X
DOI: 10.1186/s12931-020-1326-1
Popis: Abstract Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response. Moreover, prior therapeutic trials have suggested improved outcomes in these patients treated with either sulfamethoxazole/ trimethoprim or doxycycline. These trials have been limited by methodological concerns. This trial addresses the primary hypothesis that long-term treatment with antimicrobial therapy increases the time-to-event endpoint of respiratory hospitalization or all-cause mortality compared to usual care treatment in patients with IPF. We invoke numerous innovative features to achieve this goal, including: 1) utilizing a pragmatic randomized trial design; 2) collecting targeted biological samples to allow future exploration of ‘personalized’ therapy; and 3) developing a strong partnership between the NHLBI, a broad range of investigators, industry, and philanthropic organizations. The trial will randomize approximately 500 individuals in a 1:1 ratio to either antimicrobial therapy or usual care. The site principal investigator will declare their preferred initial antimicrobial treatment strategy (trimethoprim 160 mg/ sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is
Databáze: Directory of Open Access Journals
Nepřihlášeným uživatelům se plný text nezobrazuje